A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Launched by ·

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called VRDN-003 to see if it is safe and well-tolerated by people with Thyroid Eye Disease (TED), a condition that affects the eyes and can cause swelling, discomfort, and vision problems. The study also looks at how the medicine moves through the body over time. Researchers want to understand if this treatment could be helpful for people with TED.

People of all genders who have Thyroid Eye Disease may be eligible to join, as long as they meet certain age requirements. Participants will receive the study medicine and be closely monitored by the research team to check for any side effects and to see how their bodies respond to the treatment. The trial is currently recruiting volunteers, so if you or a family member has TED and are interested, this might be an option to consider after discussing it with your doctor.

Gender

ALL

Eligibility criteria